ALT Altimmune
- 7.240
- +0.050+0.70%
Altimmune News
Amgen Stock Rallies 13% on GLP-1 Weight-loss Drug Update
Express News | Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Altimmune to Participate at Two Upcoming Conferences
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on
Peering Into Altimmune's Recent Short Interest
Altimmune's (NYSE:ALT) short percent of float has risen 41.55% since its last report. The company recently reported that it has 17.73 million shares sold short, which is 25.21% of all regular shares t
Altimmune Shares Decline After Guggenheim Downgrade
Altimmune (ALT) shares were down almost 10% in recent Monday trading after Guggenheim downgraded the company's stock to neutral from buy. Trading volume stood at about 3 million shares against a daily
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it
Deutsche Bank, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Monday.Shares of Deutsche Bank Aktiengesellschaft (NYSE:DB) fell sharply in today's pre-market trading after
Express News | Altimmune Shares Are Trading Lower After Guggenheim Downgraded the Stock From Buy to Neutral
Express News | Altimmune Shares Drop 4% Premarket After Guggenheim Cuts to Neutral From Buy
Express News | Altimmune Inc : Guggenheim Cuts to Neutral From Buy
Altimmune Statement on the Passing of Dr. Stephen Harrison
GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison's family following his tragic and unexpected
TikTok to Restrict Weight Loss Drug Promotion
Popular social media platform TikTok is cracking down on most content related to weight loss drugs starting next month, according to the video-sharing site's new community guidelines published last week.
More contests are coming! Global Data: 13 new weight loss drugs are expected to be launched by 2029
Pharmacists are preparing to launch around 13 new weight loss treatments in the US within the next five years due to a surge in demand for weight loss products, according to a new report from global data analysis and consulting firm Global Data.
13 New Obesity Drugs Could Hit the Market by 2029 Amid Surging Demand
Drugmakers are preparing to launch an estimated 13 new weight-loss treatments in the U.S. over the next five years amid surging demand for the products, according to a new report by Global Data.
How Is The Market Feeling About Altimmune?
Altimmune's (NYSE:ALT) short percent of float has risen 15.72% since its last report. The company recently reported that it has 12.51 million shares sold short, which is 17.81% of all regular shares t
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Altimmune (NASDAQ:ALT) has outperformed the market over the past 5 years by 11.42% on an annualized basis producing an average annual return of 23.99%. Currently, Altimmune has a market capitalization
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
Express News | HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $12
Altimmune's Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy Rating
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
Investors might want to bet on Altimmune, Inc. (ALT), as it has been recently upgraded to a Zacks Rank #2 (Buy).
Analysis
Price Target
No Data
